Mayne Pharma Pursues ‘Aggressive Rationalization’ To Rally Revenue

Mayne Winds Up Unprofitable Generics In A Bid For Efficiency And Focus

 
• By Rosalind Rei
  
Businessman financial charts reports
Mayne has pruned its generics portfolio of unprofitable products • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business